[Preliminary assessment of ginkgo biloba (Ginkofar) in patients with dementia].
OBJECTIVE
This preliminary open-label study was undertaken to assess the efficacy and tolerability of ginkgo biloba (Ginkofar) (manufactured by Biofarm Poznań) during a 6-month period in Alzheimer type dementia, vascular and mix dementia.


METHODS
Patients were required to have at entry a diagnosis of dementia Alzheimer type or vascular according to ICD-10 criteria. The presence of both types of dementia was classified as mix dementia. 30 patients were included into the study. Overall 27 patients entered treatment and completed a 6 months period.


RESULTS
Results of clinical scales (IADL, Clock Test) during period of treatment (baseline, 3 months and 6 months) were stable. MMSE results demonstrated slight benefit.


CONCLUSIONS
The results show that ginkgo biloba was well tolerated. The patients treated with Ginkofar remaining in the study demonstrate no clinically evident loss of cognitive function.
Bidzan
Leszek
L
Klinika Psychiatrii Rozwojowej, Zaburzeń Psychotycznych i Wieku Podeszłego AM, Gdańsku.
Biliekiewicz
Adam
A
Turczyński
Jacek
J
D000328:Adult; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D003071:Cognition / Q000187:drug effects; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000523:psychology; D020441:Ginkgo biloba; D006801:Humans; D008568:Memory / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage*; D011044:Poland; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D000096983:Ginkgo Extract
D018696:Neuroprotective Agents; D010936:Plant Extracts; D014665:Vasodilator Agents; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract